Trials of Immunotherapy in Triple Negative Breast Cancer

被引：1

作者：

Gumusay, Ozge ^{[1
]}

Wabl, Chiara A. ^{[1
]}

Rugo, Hope S. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

来源：

CURRENT BREAST CANCER REPORTS | 2021年 / 13卷 / 03期

关键词：

Triple negative breast cancer; Immune checkpoint inhibitors; Immunotherapy; Atezolizumab; Pembrolizumab; PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; DOUBLE-BLIND; ANTI-PD-L1; ANTIBODY; PD-L1; EXPRESSION; PHASE-III; PROGNOSTIC VALUE; OPEN-LABEL; HIGH-RISK; PACLITAXEL;

D O I：

10.1007/s12609-021-00418-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review Triple negative breast cancer (TNBC) is an aggressive subtype with frequent chemotherapy resistance. In recent years, advances in immunotherapy have yielded promising new therapeutic strategies for the treatment of TNBC; studies evaluating immune check point inhibitors (ICIs) in combination with chemotherapy have shown encouraging results in both early and advanced stages of disease. Recent Findings Atezolizumab plus nab-paclitaxel resulted in improved progression-free survival (PFS) and overall survival (OS) compared to nab-paclitaxel alone in patients with programmed death-ligand 1-positive (PD-L1+) metastatic TNBC (mTNBC). However, atezolizumab plus paclitaxel did not improve outcomes. Pembrolizumab plus chemotherapy improved PFS compared to chemotherapy alone in patients with PD-L1+ mTNBC, and follow-up for OS is ongoing. The addition of pembrolizumab and atezolizumab to neoadjuvant chemotherapy increased pathologic complete response rates, regardless of PD-L1 status, and event-free survival is pending. Several other combinations of ICIs with targeted agents are under investigation to enhance the host immune response and are discussed in this review. TNBC has a poor prognosis with limited treatment options. Recent studies have demonstrated encouraging results by adding ICIs to chemotherapy, although optimal combinations remain to be defined. In this review, we highlight advances in TNBC treatment including ICIs and targeted agents and also discuss future directions.

引用

页码：171 / 185

页数：15

共 92 条

[1] Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study [J].

Adams, S. ;

Loi, S. ;

Toppmeyer, D. ;

Cescon, D. W. ;

De Laurentiis, M. ;

Nanda, R. ;

Winer, E. P. ;

Mukai, H. ;

Tamura, K. ;

Armstrong, A. ;

Liu, M. C. ;

Iwata, H. ;

Ryvo, L. ;

Wimberger, P. ;

Rugo, H. S. ;

Tan, A. R. ;

Jia, L. ;

Ding, Y. ;

Karantza, V. ;

Schmid, P. .

ANNALS OF ONCOLOGY, 2019, 30 (03) :405-411

[2] Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].

Adams, Sylvia ;

Diamond, Jennifer R. ;

Hamilton, Erika ;

Pohlmann, Paula R. ;

Tolaney, Sara M. ;

Chang, Ching-Wei ;

Zhang, Wei ;

Iizuka, Koho ;

Foster, Paul G. ;

Molinero, Luciana ;

Funke, Roel ;

Powderly, John .

JAMA ONCOLOGY, 2019, 5 (03) :334-342

[3] PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes [J].

Ali, H. R. ;

Glont, S. -E. ;

Blows, F. M. ;

Provenzano, E. ;

Dawson, S. -J. ;

Liu, B. ;

Hiller, L. ;

Dunn, J. ;

Poole, C. J. ;

Bowden, S. ;

Earl, H. M. ;

Pharoah, P. D. P. ;

Caldas, C. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1488-1493

[4]

Alva AS, J CLIN ONCOL

[5]

[Anonymous], COMBINED FDA APPLICA

[6] Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development [J].

Arman, E ;

Haffner-Krausz, R ;

Chen, Y ;

Heath, JK ;

Lonai, P .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :5082-5087

[7] STING: infection, inflammation and cancer [J].

Barber, Glen N. .

NATURE REVIEWS IMMUNOLOGY, 2015, 15 (12) :760-770

[8] Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1 [J].

Bertucci, Francois ;

Goncalves, Anthony .

CURRENT ONCOLOGY REPORTS, 2017, 19 (10)

[9] Combinatorial strategies for the induction of immunogenic cell death [J].

Bezu, Lucillia ;

Gomes-de-Silva, Ligia C. ;

Dewitte, Heleen ;

Breckpot, Karine ;

Fucikova, Jitka ;

Spisek, Radek ;

Galluzzi, Lorenzo ;

Kepp, Oliver ;

Kroemer, Guido .

FRONTIERS IN IMMUNOLOGY, 2015, 6

[10] TUMOR-ANTIGENS RECOGNIZED BY T-LYMPHOCYTES [J].

BOON, T ;

CEROTTINI, JC ;

VANDENEYNDE, B ;

VANDERBRUGGEN, P ;

VANPEL, A .

ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :337-365

← 1 2 3 4 5 6 7 8 9 10 →